247 related articles for article (PubMed ID: 24354797)
1. Expression of insulin-like growth factor-1 receptor in metastatic uveal melanoma and implications for potential autocrine and paracrine tumor cell growth.
Yoshida M; Selvan S; McCue PA; DeAngelis T; Baserga R; Fujii A; Rui H; Mastrangelo MJ; Sato T
Pigment Cell Melanoma Res; 2014 Mar; 27(2):297-308. PubMed ID: 24354797
[TBL] [Abstract][Full Text] [Related]
2. Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target.
All-Ericsson C; Girnita L; Seregard S; Bartolazzi A; Jager MJ; Larsson O
Invest Ophthalmol Vis Sci; 2002 Jan; 43(1):1-8. PubMed ID: 11773005
[TBL] [Abstract][Full Text] [Related]
3. c-Met, epidermal growth factor receptor, and insulin-like growth factor-1 receptor are important for growth in uveal melanoma and independently contribute to migration and metastatic potential.
Wu X; Zhou J; Rogers AM; Jänne PA; Benedettini E; Loda M; Hodi FS
Melanoma Res; 2012 Apr; 22(2):123-32. PubMed ID: 22343486
[TBL] [Abstract][Full Text] [Related]
4. [Clinicopathological significance of expression of IGF-1R in uveal melanoma and its association with expression of p-AKT Thr308].
Bao XL; Song H; Tang X
Zhonghua Yan Ke Za Zhi; 2012 May; 48(5):413-6. PubMed ID: 22932330
[TBL] [Abstract][Full Text] [Related]
5. Correlation of clinicopathological parameters with HGF, c-Met, EGFR, and IGF-1R expression in uveal melanoma.
Topcu-Yilmaz P; Kiratli H; Saglam A; Söylemezoglu F; Hascelik G
Melanoma Res; 2010 Apr; 20(2):126-32. PubMed ID: 20061986
[TBL] [Abstract][Full Text] [Related]
6. Pristimerin attenuates cell proliferation of uveal melanoma cells by inhibiting insulin-like growth factor-1 receptor and its downstream pathways.
Xie X; Xie S; Xie C; Fang Y; Li Z; Wang R; Jiang W
J Cell Mol Med; 2019 Nov; 23(11):7545-7553. PubMed ID: 31508890
[TBL] [Abstract][Full Text] [Related]
7. Receptors for the liver synthesized growth factors IGF-1 and HGF/SF in uveal melanoma: intercorrelation and prognostic implications.
Economou MA; All-Ericsson C; Bykov V; Girnita L; Bartolazzi A; Larsson O; Seregard S
Acta Ophthalmol; 2008 Nov; 86 Thesis 4():20-5. PubMed ID: 19032678
[TBL] [Abstract][Full Text] [Related]
8. Receptors for the liver synthesized growth factors IGF-1 and HGF/SF in uveal melanoma: intercorrelation and prognostic implications.
Economou MA; All-Ericsson C; Bykov V; Girnita L; Bartolazzi A; Larsson O; Seregard S
Invest Ophthalmol Vis Sci; 2005 Dec; 46(12):4372-5. PubMed ID: 16303922
[TBL] [Abstract][Full Text] [Related]
9. The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells.
Girnita A; All-Ericsson C; Economou MA; Aström K; Axelson M; Seregard S; Larsson O; Girnita L
Acta Ophthalmol; 2008 Nov; 86 Thesis 4():26-34. PubMed ID: 19032679
[TBL] [Abstract][Full Text] [Related]
10. Elucidating the role of the FoxO3a transcription factor in the IGF-1-induced migration and invasion of uveal melanoma cancer cells.
Yan F; Liao R; Farhan M; Wang T; Chen J; Wang Z; Little PJ; Zheng W
Biomed Pharmacother; 2016 Dec; 84():1538-1550. PubMed ID: 27881235
[TBL] [Abstract][Full Text] [Related]
11. Oral picropodophyllin (PPP) is well tolerated in vivo and inhibits IGF-1R expression and growth of uveal melanoma.
Economou MA; Andersson S; Vasilcanu D; All-Ericsson C; Menu E; Girnita A; Girnita L; Axelson M; Seregard S; Larsson O
Acta Ophthalmol; 2008 Nov; 86 Thesis 4():35-41. PubMed ID: 19032680
[TBL] [Abstract][Full Text] [Related]
12. The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells.
Girnita A; All-Ericsson C; Economou MA; Aström K; Axelson M; Seregard S; Larsson O; Girnita L
Clin Cancer Res; 2006 Feb; 12(4):1383-91. PubMed ID: 16489097
[TBL] [Abstract][Full Text] [Related]
13. Oral picropodophyllin (PPP) is well tolerated in vivo and inhibits IGF-1R expression and growth of uveal melanoma.
Economou MA; Andersson S; Vasilcanu D; All-Ericsson C; Menu E; Girnita A; Girnita L; Axelson M; Seregard S; Larsson O
Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2337-42. PubMed ID: 18515579
[TBL] [Abstract][Full Text] [Related]
14. Prognostic associations of insulin-like growth factor-1 receptor in primary uveal melanoma.
Al-Jamal RT; Kivelä T
Can J Ophthalmol; 2011 Dec; 46(6):471-6. PubMed ID: 22153631
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive analysis of receptor tyrosine kinase activation in human melanomas reveals autocrine signaling through IGF-1R.
Molhoek KR; Shada AL; Smolkin M; Chowbina S; Papin J; Brautigan DL; Slingluff CL
Melanoma Res; 2011 Aug; 21(4):274-84. PubMed ID: 21654344
[TBL] [Abstract][Full Text] [Related]
16. Insulin-like growth factor-binding protein-3 inhibits IGF-1-induced proliferation of human hepatocellular carcinoma cells by controlling bFGF and PDGF autocrine/paracrine loops.
Ma Y; Han CC; Li Y; Wang Y; Wei W
Biochem Biophys Res Commun; 2016 Sep; 478(2):964-9. PubMed ID: 27521890
[TBL] [Abstract][Full Text] [Related]
17. Uveal melanoma and macular degeneration: molecular biology and potential therapeutic applications.
Economou MA
Acta Ophthalmol; 2008 Dec; 86(8):930-1. PubMed ID: 19086934
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA 145 may play an important role in uveal melanoma cell growth by potentially targeting insulin receptor substrate-1.
Li Y; Huang Q; Shi X; Jin X; Shen L; Xu X; Wei W
Chin Med J (Engl); 2014; 127(8):1410-6. PubMed ID: 24762580
[TBL] [Abstract][Full Text] [Related]
19. HDAC Inhibition Enhances the
Faião-Flores F; Emmons MF; Durante MA; Kinose F; Saha B; Fang B; Koomen JM; Chellappan SP; Maria-Engler SS; Rix U; Licht JD; Harbour JW; Smalley KSM
Clin Cancer Res; 2019 Sep; 25(18):5686-5701. PubMed ID: 31227503
[TBL] [Abstract][Full Text] [Related]
20. The relationship between the insulin-like growth factor-1 system and the oestrogen metabolising enzymes in breast cancer tissue and its adjacent non-cancerous tissue.
Chong YM; Colston K; Jiang WG; Sharma AK; Mokbel K
Breast Cancer Res Treat; 2006 Oct; 99(3):275-88. PubMed ID: 16752221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
